Home  |  About SITC  |  Facebook  |  Twitter  |  LinkedIn  |  YouTube  |  Oncology Tube  |  Sitemap

Advances in Cancer Immunotherapy™ - La Jolla, CA


Friday, August 22, 2014
8:00 am - 3:30 pm
Fairway I & IV
Hilton La Jolla Torrey Pines
10950 North Torrey Pines Road                                                           
La Jolla, CA 92037

CME-certified regional program


Gregory A. Daniels, MD, PhD – University of California San Diego Cancer Center
Omid Hamid, MD – The Angeles Clinic and Research Institute

Planning Committee

Asim Amin, MD, PhD – Levine Cancer Institute Carolinas Medical Center
Joseph W. Fay, MD – Baylor University Medical Center
Keith L. Knutson, PhD – Vaccine & Gene Therapy Institute of Florida
John D. Powderly II, MD, CPI – Carolina BioOncology Institute, PLLC
Brian I. Rini, MD – Cleveland Clinic Taussig Cancer Center
Alexander Spira, MD, PhD – Virginia Cancer Specialists


Specifically designed for clinical oncologists and the entire medical team involved in treating cancer patients with immunotherapy, this program provided an understanding of basic immunology principles underlying the clinical application of immunotherapy, provided insights into the indications and clinical management of patients receiving tumor immunotherapy, and discussed concepts in the tumor immunotherapy field.

Presented by leading authorities in tumor immunology and cancer immunotherapy, this program reviewed the basics of the immune system and its relationship to cancer, summarized central themes in tumor immunotherapy, and described how the immune system is influenced by standard cancer treatments. It also addressed how immunotherapy can be combined with other immunotherapy agents and with chemotherapy or radiation therapy to improve therapeutic responses.

Attendees also took advantage of the opportunity for professional networking that promotes collaboration and scientific exchange with experts, clinical oncologists and other health care providers.

Intended Audience

The target audience for this program included clinical oncologists, those involved in patient care, early career individuals, allied health professionals, and patient advocates who wish to learn principles of tumor immunology and immunotherapy, as well as improve their ability to select patients for immunotherapy and provide state-of-the-art clinical management for their patients.

Session Topics

  • Biomarkers: How to Select the Correct Patient for Which Therapy
  • Cell Therapy
  • Combination Therapy
  • Current State of Immune Checkpoint Inhibitors
  • Immune Changes Associated with Tumor Growth and Regression
  • Immunology 101
  • Inflammation and Tumor Development
  • Oncolytic Virus Therapy in Cancer Immunotherapy
  • Radiation and Immune Therapy

Educational Objectives

Upon completion of this program, the participants are able to:

  • Interpret the key principles of tumor immunology and immunotherapy
  • Analyze recent research and clinical applications of cytokines, cancer vaccines, T cell checkpoint inhibitors, adoptive immunotherapy and biomarkers
  • Participate in scientific exchange with local colleagues, potential collaborators, and subject matter experts on research and clinical application of cancer immunotherapy
  • Implement cancer immunotherapy treatments into clinical practice more effectively through a sound understanding of how they work, the clinical management of patients, and the potential to improve patient outcomes with tumor immunotherapy

Jointly provided by Clinical Immunology Society (CIS) and Society for Immunotherapy of Cancer (SITC)

The Advances of Cancer ImmunotherapyTM series is supported in part by educational grants from:

  • AstraZeneca
  • Bristol-Myers Squibb
  • Dendreon
  • Merck
  • Prometheus

To view all of SITC’s supporters, please, click here.

Society for Immunotherapy of Cancer
555 East Wells Street, Suite 1100  |  Milwaukee, WI 53202-3823 USA
Tel: +1 414 271 2456  |  Fax: +1 414 276 3349  |  Email: info@sitcancer.org
About SITC  |  Membership  |  Journal  |  Meetings  |  Resources  |  Support SITC
© 2016 Society for Immunotherapy of Cancer. All rights reserved.